...
首页> 外文期刊>Journal of cardiothoracic and vascular anesthesia >A new plasma-adapted hydroxyethyl starch preparation: in vitro coagulation studies.
【24h】

A new plasma-adapted hydroxyethyl starch preparation: in vitro coagulation studies.

机译:一种新的适应血浆的羟乙基淀粉制剂:体外凝血研究。

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVE: Preparing hydroxyethyl starch (HES) in a plasma-adapted solution is supposed to improve safety with regard to coagulation. The influence of a new plasma-adapted HES preparation on coagulation was studied. DESIGN: Operator-blinded, randomized study. SETTING: Laboratory in vitro study. PARTICIPANTS: Fifteen healthy young men scheduled for blood donation. INTERVENTIONS: Blood was diluted by 10%, 30%, and 50% using either a plasma-adapted or nonplasma-adapted (prepared in saline solution) potato-derived 6% HES 130/0.42. Only the composition of the solvent of the 2 HES preparations was different. MEASUREMENTS AND MAIN RESULTS: Rotation thromboelastometry (ROTEM; Pentapharm, Munich, Germany) was used to assess changes in coagulation; whole blood aggregometry with 3 inducers was used to assess effects of dilution with HES on platelet function. Clotting time (CT) and clot formation time were significantly prolonged by 30% and 50% dilution, showing significantly longer times in the non-plasma-adapted than in the plasma-adapted HES group (eg, intrinsic CT at the 30% dilution level: plasma-adapted HES 228 +/- 26 seconds [within normal range] v 269 +/- 29 seconds in the nonplasma-adapted HES group). Clot strengthening and clot firmness were significantly reduced by the non-plasma-adapted HES at the 30% dilution level. Platelet aggregation was significantly more reduced by the non-plasma-adapted HES at the 30% and 50% dilution levels. CONCLUSIONS: Dilution with the nonplasma-adapted HES 130/0.42 was associated with more negative effects on thromboelastometry and platelet aggregation than the same HES 130/0.4 dissolved in a plasma-adapted solution. The benefits of using a plasma-adapted modern HES preparation on blood loss and use of blood/blood products in cardiac surgery need to be studied.
机译:目的:在适应血浆的溶液中制备羟乙基淀粉(HES)可以提高凝血的安全性。研究了新的血浆适应性HES制剂对凝血的影响。设计:操作员盲法,随机研究。地点:实验室体外研究。参与者:15名健康的年轻人计划进行献血。干预措施:使用血浆来源的或非血浆来源的(在盐水溶液中制备)马铃薯衍生的6%HES 130 / 0.42将血液稀释10%,30%和50%。 2种HES制剂的溶剂组成不同。测量和主要结果:旋转血栓弹力测定法(ROTEM;德国慕尼黑Pentapharm公司)用于评估凝血的变化。用3种诱导剂的全血凝集法评估HES稀释对血小板功能的影响。凝血时间(CT)和凝块形成时间显着延长了30%和50%稀释,与非血浆适应性HES组相比,非血浆适应性显着更长的时间(例如,稀释度为30%的内在CT :在非血浆适应性HES组中,适应血浆的HES 228 +/- 26秒(在正常范围内)对269 +/- 29秒)。在30%的稀释水平下,非血浆适应性HES显着降低了血凝块增强和血凝块硬度。在30%和50%稀释水平下,非血浆适应性HES可以显着减少血小板聚集。结论:与非血浆适应性HES 130 / 0.42稀释相比,溶血于血浆适应性溶液中的相同HES 130 / 0.4对血栓弹力测定法和血小板凝集的负面影响更大。需要研究使用适合血浆的现代HES制剂在心脏手术中对失血和使用血液/血液制品的益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号